Joint Transnational Call 2016 (JTC2016)

HCQ4Surfdefect

Among children with interstitial lung diseases (chILD) the surfactant dysfunction disorders play an important role, but no proven treatments are available. During the last 30 years and based on anecdotal reports, hydroxychloroquine, a drug usually used for malaria treatment, has been tried to treat chILD.
The goals of this project are to investigate if the start or the withdrawal of hydroxychloroquine treatment will alter the oxygenation compared to placebo in patients with surfactant dysfunction disorders. Among others, quality of life, and costs will be assessed. The study will be done by teams in Austria, Germany, Italy, Poland, Portugal, Spain and Turkey. We hope to establish a safe and effective way to treat these forms of chILD.

  • Griese, Matthias (Coordinator)
    Dr. Von Hauner Children’s Hospital, University of Munich [GERMANY]
  • Moreno Galdó, Antonio
    Hospital Universitari Vall d’Hebron [SPAIN]
  • Krenke, Katarzyna
    Medical University of Warsaw [POLAND]
  • Cutrera, Renato
    Bambino Gesù Children Hospital [ITALY]
  • Kiper, Nural
    Hacettepe University, Faculty of Medicine [TURKEY]
  • Szépfalusi, Zsolt
    Medical University of Vienna [AUSTRIA]
  • Bandeira, Teresa
    Centro Hospitalar Lisboa Norte, Hospital de Santa Maria [PORTUGAL]
  • Kronfeld, Kai
    Medical School of the University Mainz [GERMANY]